Acesis Holdings Corporation (ACSB)
Acesis Holdings will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $6.00
Shares Offered
1,300,000
Deal Size
$6.50M

Company Description

Acesis Holdings Corporation together with its wholly-owned subsidiaries, is an emerging, pre-phase 1 (first-in-man “FIM”) clinical, biotechnology company focused on men’s health.

Since the incorporation of ABI in the State of Colorado on March 11, 2015, we have been developing novel treatments for low testosterone levels in males (“Low–T”).

The Company’s point of differentiation, compared to its competitors, is that its drug pipeline (peptides) is not a steroid or a hormone, but is intended to induce the body (specifically, the testes, which is the major natural site of T synthesis in men) to produce its own testosterone.

The Company’s lead peptide, ACE-167, has been designed to act through a novel molecular mechanism to induce the Leydig cells of the testis to synthesize testosterone thereby restoring endogenous T production.

The unique attributes of ACE-167, including its novel mechanism of action and non-steroidal composition, and its ability to induce endogenous levels of T production will need to be proven by the completion of clinical trials and regulatory review.

It is our goal to prove that product candidate ACE-167 does not confer the adverse effects in the body as reported for the marketed T formulations.

Acesis Holdings Corporation
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees2
CEOKonstantinos Karatzas

Contact Details

Address:
9233 Park Meadows Dr., Ste. 108
Lone Tree, CO 80124
United States
Phone(720) 389-0650
Websiteacesisbio.com

Stock Details

Ticker SymbolACSB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001955728
Employer ID88-4251528
SIC Code2836

Key Executives

NamePosition
Dr. Konstantinos KaratzasChief Executive Officer, Director
Dr. Vassilios PapadopoulosDirector
Duane Charles Knight, JrChief Financial Officer and Treasurer
Thomas B. OlsonChief Operating Officer and Corporate Secretary

Latest SEC Filings

DateTypeTitle
Jun 30, 2025C/AFiling
Apr 29, 2025C/AFiling
Apr 1, 2025C/AFiling
Mar 17, 2025CFiling
Sep 15, 2023S-1General form for registration of securities under the Securities Act of 1933
Jun 30, 2023DRS/A[Amend] [Cover] Draft Registration Statement
Jun 9, 2023D/AFiling
May 12, 2023DRS/A[Amend] [Cover] Draft Registration Statement
Apr 7, 2023D/AFiling
Mar 1, 2023D/AFiling